Picture loading failed.

Pre-Made Prezalumab biosimilar, Whole mAb, Anti-ICOSLG/B7RP1 Antibody: Anti-B7-H2/B7H2/B7h/CD275/GL50/ICOS-L/ICOSL/LICOS therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Prezalumab is an IgG2 type monoclonal antibody designed to bind to ICOSL, inhibiting the interaction between ICOSL and ICOS and reducing the body's autoimmune response.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-456-1mg 1mg 3090
GMP-Bios-ab-456-10mg 10mg 21890
GMP-Bios-ab-456-100mg 100mg 148000
GMP-Bios-ab-456-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Prezalumab biosimilar, Whole mAb, Anti-ICOSLG/B7RP1 Antibody: Anti-B7-H2/B7H2/B7h/CD275/GL50/ICOS-L/ICOSL/LICOS therapeutic antibody
INN Name Prezalumab
TargetB7RP1
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure6x4t:BE:DF
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesAmgen;MedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCutaneous lupus erythematosus;Psoriasis;Sjogren's syndrome;Systemic lupus erythematosus
Development Techna